Stifel Nicolaus Has Lowered Expectations for Nyxoah (NASDAQ:NYXH) Stock Price

Nyxoah (NASDAQ:NYXH) had its target price dropped by analysts at Stifel Nicolaus from $16.00 to $15.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 42.72% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Nyxoah in a report on Friday, December 13th.

Nyxoah Trading Up 4.6 %

Shares of NYXH opened at $10.51 on Friday. The firm has a market cap of $357.97 million, a price-to-earnings ratio of -5.62 and a beta of 1.42. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. Nyxoah has a fifty-two week low of $6.76 and a fifty-two week high of $20.00. The firm has a 50 day moving average price of $10.29 and a 200-day moving average price of $9.19.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). The business had revenue of $1.35 million during the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. As a group, equities research analysts forecast that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NYXH. Vestal Point Capital LP purchased a new position in shares of Nyxoah in the fourth quarter worth $23,394,000. Renaissance Technologies LLC purchased a new position in shares of Nyxoah in the fourth quarter worth $187,000. Ameriprise Financial Inc. purchased a new position in shares of Nyxoah in the fourth quarter worth $135,000. LPL Financial LLC purchased a new position in shares of Nyxoah in the fourth quarter worth $102,000. Finally, Kovack Advisors Inc. increased its stake in shares of Nyxoah by 100.0% in the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock worth $160,000 after buying an additional 10,000 shares during the period.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.